AMGN

Amgen Inc. 10-Q Summary: Quarter Ended September 30, 2025

Business Context and Reporting Period

This filing is a Quarterly Report on Form 10-Q for Amgen Inc., a global biotechnology company operating in a single segment: human therapeutics. The report covers the three and nine months ended September 30, 2025. As of October 30, 2025, the company had 538.5 million shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 12% in Q3 and 10% for the nine months ended September 30, 2025, compared to the prior year. Product sales grew 12% (Q3) and 11% (9M), driven by volume growth of 14% partially offset by net selling price declines of 4% and 3%, respectively.
• Profitability Surge: Net income increased 14% in Q3 and 84% for the nine-month period. The significant year-to-date increase was driven by higher net unrealized gains on equity investments (primarily BeOne Medicines Ltd.) and lower amortization expenses from inventory step-up adjustments.
• Expense Increases: Operating expenses rose 9% in Q3 and 6% for the nine months. This was driven by increased R&D spending on Later-Stage Clinical Programs and $1.2 billion in Otezla intangible asset impairment charges recorded in the first nine months of 2025 due to CMS Medicare price setting selections.
• Debt Reduction: The company repaid $5.0 billion of debt and repurchased $1.0 billion of debt principal during the first nine months of 2025, resulting in a $264 million gain on extinguishment.

Guidance, Outlook, and Risks

• Product Developments:
  • Repatha: FDA broadened approval in August 2025 to include adults at increased risk for major adverse cardiovascular events without prior CV disease. Phase 3 VESALIUS-CV trial met endpoints in October 2025.
  • TEZSPIRE: FDA approved add-on maintenance treatment for chronic rhinosinusitis with nasal polyps in October 2025.
  • Otezla: Selected for Medicare price setting effective January 1, 2027, leading to impairment charges and expected future net selling price declines.
  • ENBREL: Sales declined 30% in Q3 due to Medicare Part D redesign and 340B Program mix impacts.
• Capital Allocation: The company paid quarterly dividends of $2.38 per share (a 6% increase over 2024). No stock repurchases were made under the program in the first nine months of 2025; $6.8 billion of authorization remains available.
• Regulatory and Tax Risks:
  • IRS Dispute: Amgen is contesting IRS Notices for tax years 2010–2015 in U.S. Tax Court, involving potential additional federal taxes of approximately $8.7 billion plus penalties. A decision is expected no earlier than the second half of 2026.
  • Tariffs: New tariffs and trade protection measures (including July 2025 Executive Orders) are expected to increase manufacturing and operating expenses in future quarters.
  • Drug Pricing: The Inflation Reduction Act (IRA) and Most-Favored-Nations (MFN) Executive Order pose ongoing risks to pricing and reimbursement.

Investor Verification Checklist

• Otezla Impairment: Verify the impact of the $1.2 billion impairment charge on future cash flow projections and the timeline for Medicare price setting implementation in 2027.
• IRS Litigation Outcome: Monitor the U.S. Tax Court proceedings regarding the 2010–2015 tax dispute, as an adverse ruling could result in significant tax liabilities.
• Repatha Expansion: Assess the commercial impact of the expanded FDA indication and positive VESALIUS-CV trial results on future revenue growth.
• Tariff Exposure: Evaluate the specific impact of new U.S. tariffs and retaliatory measures on manufacturing costs and supply chain logistics.
• Debt Strategy: Confirm the company's continued ability to service debt while maintaining dividend payments and funding R&D, given the reduction in cash equivalents from $11.9 billion to $9.4 billion.